Dimethyllysergamide
Dimethyllysergamide[edit]
Dimethyllysergamide (also known as DAM-57) is a chemical compound belonging to the ergoline family. It is a derivative of lysergic acid and is structurally related to lysergic acid diethylamide (LSD). Dimethyllysergamide is of interest in the field of psychopharmacology due to its potential psychoactive properties.
Chemical Structure and Properties[edit]
Dimethyllysergamide is characterized by its ergoline backbone, which is a tetracyclic structure. The compound is a lysergamide, meaning it is an amide of lysergic acid. The chemical structure of Dimethyllysergamide includes two methyl groups attached to the nitrogen atom of the amide group, distinguishing it from other lysergamides such as LSD, which has ethyl groups instead.
Pharmacology[edit]
The pharmacological effects of Dimethyllysergamide are not as well-studied as those of LSD. However, it is believed to interact with the serotonin receptors in the brain, similar to other compounds in the ergoline family. This interaction is thought to be responsible for its potential psychoactive effects.
Synthesis[edit]
The synthesis of Dimethyllysergamide involves the chemical modification of lysergic acid. The process typically includes the formation of the amide bond between lysergic acid and dimethylamine. This synthesis requires careful control of reaction conditions to ensure the correct formation of the desired product.
Potential Uses and Research[edit]
Research into Dimethyllysergamide is limited, but it is of interest for its potential use in psychedelic therapy and as a tool for understanding the neurobiology of consciousness. Studies on similar compounds have shown promise in treating conditions such as depression and post-traumatic stress disorder (PTSD).
Legal Status[edit]
The legal status of Dimethyllysergamide varies by country. In many places, it is not specifically scheduled, but it may be considered an analogue of LSD and thus subject to similar legal restrictions under analogue laws.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
